Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia.

Tropea TF, Mak J, Guo MH, Xie SX, Suh E, Rick J, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Trojanowski JQ, Van Deerlin V, Chen-Plotkin AS.

Ann Neurol. 2019 Jun;85(6):801-811. doi: 10.1002/ana.25486.

PMID:
30973966
2.

Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.

Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B.

Alzheimers Res Ther. 2019 Mar 13;11(1):23. doi: 10.1186/s13195-019-0476-1.

3.

Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board.

Parkinsonism Relat Disord. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31.

PMID:
30738748
4.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

5.

Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.

Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D, McMillan CT, Wolk DA, Akhtar RS, Hurtig HI, Branch Coslett H, Hamilton RH, Siderowf AD, Duda JE, Rascovsky K, Lee EB, Lee VM, Grossman M, Trojanowski JQ, Irwin DJ.

Ann Neurol. 2019 Feb;85(2):259-271. doi: 10.1002/ana.25392. Epub 2019 Jan 7.

6.

The importance of preclinical diagnostics in Parkinson disease.

Mantri S, Morley JF, Siderowf AD.

Parkinsonism Relat Disord. 2018 Sep 11. pii: S1353-8020(18)30396-1. doi: 10.1016/j.parkreldis.2018.09.011. [Epub ahead of print] Review.

PMID:
30224266
7.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative.

PLoS One. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018.

8.

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.

Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM, Trojanowski JQ.

Brain. 2018 Jul 1;141(7):2181-2193. doi: 10.1093/brain/awy146.

PMID:
29878075
9.

Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials.

Siderowf A, Aarsland D, Mollenhauer B, Goldman JG, Ravina B.

Mov Disord. 2018 Apr;33(4):528-536. doi: 10.1002/mds.27355. Review.

PMID:
29624752
10.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*.

Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.

11.

Biomarkers for atypical Parkinsonism: Some progress, but much work remains.

Feigin A, Siderowf A.

Parkinsonism Relat Disord. 2018 Mar;48:1-2. doi: 10.1016/j.parkreldis.2018.02.025. No abstract available.

PMID:
29478511
12.

CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.

Irwin DJ, Xie SX, Coughlin D, Nevler N, Akhtar RS, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, Duda JE, Spindler M, Siderowf A, Hurtig HI, Shaw LM, Grossman M, Trojanowski JQ.

Neurology. 2018 Mar 20;90(12):e1038-e1046. doi: 10.1212/WNL.0000000000005166. Epub 2018 Feb 21.

13.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13. Review.

14.

Observations on a 2-Step Approach to Screening for Parkinson Disease-Reply.

Jennings D, Siderowf A, Marek K.

JAMA Neurol. 2017 Dec 1;74(12):1506-1507. doi: 10.1001/jamaneurol.2017.3208. No abstract available.

PMID:
29114721
15.

Cognition and the course of prodromal Parkinson's disease.

Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators.

Mov Disord. 2017 Nov;32(11):1640-1645. doi: 10.1002/mds.27189. Epub 2017 Oct 24.

16.

18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.

Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD Sr, Tsai R, Winer J, Russell DS, Litvan I, Roberson ED, Seeley WW, Grinberg LT, Kramer JH, Miller BL, Pressman P, Nasrallah I, Baker SL, Gomperts SN, Johnson KA, Grossman M, Jagust WJ, Boxer AL, Rabinovici GD.

Ann Neurol. 2017 Oct;82(4):622-634. doi: 10.1002/ana.25060.

17.

Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.

Fullard ME, Xie SX, Marek K, Stern M, Jennings D, Siderowf A, Willis AW, Chen-Plotkin AS.

Mov Disord. 2017 Nov;32(11):1636-1640. doi: 10.1002/mds.27127. Epub 2017 Sep 14.

18.

Effectiveness of Florbetapir PET Imaging in Changing Patient Management.

Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, Nobili F, Sadowsky CH, Salloway S, Arora AK, Chevrette A, Deberdt W, Dell'Agnello G, Flitter M, Galante N, Lowrey MJ, Lu M, McGeehan A, Devous MD Sr, Mintun MA.

Dement Geriatr Cogn Disord. 2017;44(3-4):129-143. doi: 10.1159/000478007. Epub 2017 Aug 5.

19.

Portable objective assessment of upper extremity motor function in Parkinson's disease.

Chahine LM, Uribe L, Hogarth P, McNames J, Siderowf A, Marek K, Jennings D.

Parkinsonism Relat Disord. 2017 Oct;43:61-66. doi: 10.1016/j.parkreldis.2017.07.017. Epub 2017 Jul 19.

PMID:
28747279
20.

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators.

JAMA Neurol. 2017 Aug 1;74(8):933-940. doi: 10.1001/jamaneurol.2017.0985.

21.

Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.

Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS, Hurtig HI, Siderowf AD, Dubroff JG, Weintraub D.

PLoS One. 2017 May 25;12(5):e0177924. doi: 10.1371/journal.pone.0177924. eCollection 2017.

22.

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D; Parkinson’s Progression Markers Initiative (PPMI).

PLoS One. 2017 May 17;12(5):e0175674. doi: 10.1371/journal.pone.0175674. eCollection 2017.

23.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

24.

Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging.

Pontecorvo MJ, Arora AK, Devine M, Lu M, Galante N, Siderowf A, Devadanam C, Joshi AD, Heun SL, Teske BF, Truocchio SP, Krautkramer M, Devous MD Sr, Mintun MA.

Eur J Nucl Med Mol Imaging. 2017 May;44(5):825-837. doi: 10.1007/s00259-016-3601-4. Epub 2017 Jan 7.

PMID:
28064343
25.

Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia.

Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD.

Mov Disord Clin Pract. 2016 Jul-Aug;3(4):367-375. Epub 2016 Jan 5.

26.

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.

Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A; PARS Investigators; Alzheimer's Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS.

Ann Clin Transl Neurol. 2016 Mar 29;3(5):346-55. doi: 10.1002/acn3.299. eCollection 2016 May.

27.

Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.

Shulman LM, Armstrong M, Ellis T, Gruber-Baldini A, Horak F, Nieuwboer A, Parashos S, Post B, Rogers M, Siderowf A, Goetz CG, Schrag A, Stebbins GT, Martinez-Martin P.

Mov Disord. 2016 Oct;31(10):1455-1465. doi: 10.1002/mds.26649. Review.

PMID:
27193358
28.

The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease.

Brennan L, Siderowf A, Rubright JD, Rick J, Dahodwala N, Duda JE, Hurtig H, Stern M, Xie SX, Rennert L, Karlawish J, Shea JA, Trojanowski JQ, Weintraub D.

Parkinsonism Relat Disord. 2016 Apr;25:21-6. doi: 10.1016/j.parkreldis.2016.02.020. Epub 2016 Feb 21.

29.

Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease.

Nowinski CJ, Siderowf A, Simuni T, Wortman C, Moy C, Cella D.

Mov Disord. 2016 May;31(5):725-33. doi: 10.1002/mds.26546. Epub 2016 Feb 26. Review.

PMID:
26919664
30.

Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.

Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, Mintun MA, Pontecorvo MJ; 18F-AV-45-A17 Study Group.

Dement Geriatr Cogn Disord. 2016;41(1-2):80-92. doi: 10.1159/000441139. Epub 2016 Jan 8.

PMID:
26745445
31.

Longitudinal study of normal cognition in Parkinson disease.

Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D.

Neurology. 2015 Oct 13;85(15):1276-82. doi: 10.1212/WNL.0000000000002001. Epub 2015 Sep 11.

32.

Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.

Chahine LM, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators.

Mov Disord. 2016 Jan;31(1):86-94. doi: 10.1002/mds.26373. Epub 2015 Aug 21.

33.

Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire.

Brennan L, Siderowf A, Rubright JD, Rick J, Dahodwala N, Duda JE, Hurtig H, Stern M, Xie SX, Rennert L, Karlawish J, Shea JA, Trojanowski JQ, Weintraub D.

Mov Disord. 2016 Jan;31(1):126-34. doi: 10.1002/mds.26339. Epub 2015 Aug 7.

34.

Author Response.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K.

Neurology. 2015 Jun 2;84(22):2292. No abstract available.

PMID:
26230002
35.

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; Parkinson's Progression Markers Initiative.

Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4.

36.

Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators.

Neurology. 2014 Nov 4;83(19):1739-46. doi: 10.1212/WNL.0000000000000960. Epub 2014 Oct 8.

37.

Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference.

Sieber BA, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR, Dunlop J, Finkbeiner S, Sutherland M, Wang H, Lee VM, Orr HT, Gwinn K, Ludwig K, Taylor A, Torborg C, Montine TJ; Parkinson's Disease 2014: Advancing Research, Improving Lives Conference Organizing Committee.

Ann Neurol. 2014 Oct;76(4):469-72. doi: 10.1002/ana.24261. Epub 2014 Sep 23. No abstract available.

38.

People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.

Burdick DJ, Cholerton B, Watson GS, Siderowf A, Trojanowski JQ, Weintraub D, Ritz B, Rhodes SL, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Srivatsal S, Edwards KL, Montine TJ, Zabetian CP, Leverenz JB.

Mov Disord. 2014 Sep;29(10):1258-64. doi: 10.1002/mds.25924. Epub 2014 Jul 29.

39.

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE, Minger J, Weintraub D.

Neurology. 2014 Aug 26;83(9):826-33. doi: 10.1212/WNL.0000000000000729. Epub 2014 Jul 18.

40.

β-Amyloid in CSF: a window into Parkinson disease dementia.

Siderowf A, Logroscino G.

Neurology. 2014 May 20;82(20):1758-9. doi: 10.1212/WNL.0000000000000437. Epub 2014 Apr 18. No abstract available.

PMID:
24748673
41.

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.

Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, Lu M, Adler CH, Galasko D, Liebsack C, Skovronsky DM, Sabbagh MN.

BMC Neurol. 2014 Apr 9;14:79. doi: 10.1186/1471-2377-14-79.

42.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
43.

Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database.

Gaugler JE, Ascher-Svanum H, Roth DL, Fafowora T, Siderowf A, Beach TG.

BMC Geriatr. 2013 Dec 19;13:137. doi: 10.1186/1471-2318-13-137.

44.

Bridging the credibility gap in cost effectiveness analysis.

Siderowf A.

Mov Disord. 2014 Feb;29(2):164-5. doi: 10.1002/mds.25758. Epub 2013 Dec 11. No abstract available.

PMID:
24338647
45.

Mobility, mood and site of care impact health related quality of life in Parkinson's disease.

Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, Okun MS, Simuni T, Parashos SA, Dahodwala NA, Davis TL, Giladi N, Gurevich T, Hauser RA, Jankovic J, Lyons KE, Marsh L, Miyasaki JM, Morgan JC, Santiago AJ, Tarsy D, Mari Z, Malaty IA, Nelson EC; National Parkinson Foundation Quality Improvement Initiative Investigators.

Parkinsonism Relat Disord. 2014 Mar;20(3):274-9. doi: 10.1016/j.parkreldis.2013.10.004. Epub 2013 Oct 16.

PMID:
24182524
46.

Author response.

Weintraub D, Siderowf A, Papay K.

Neurology. 2013 Aug 13;81(7):694-5. No abstract available.

PMID:
24137626
47.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

48.

Daytime sleepiness is associated with falls in Parkinson's disease.

Spindler M, Gooneratne NS, Siderowf A, Duda JE, Cantor C, Dahodwala N.

J Parkinsons Dis. 2013 Jan 1;3(3):387-91. doi: 10.3233/JPD-130184.

49.

Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.

Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC, Ritz B, Siderowf AD, Tanner CM, Tröster AI, Zhang J.

Environ Health Perspect. 2013 Nov-Dec;121(11-12):1245-52. doi: 10.1289/ehp.1306967. Epub 2013 Aug 9. Review.

50.

Costs of Parkinson's disease in a privately insured population.

Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD.

Pharmacoeconomics. 2013 Sep;31(9):799-806. doi: 10.1007/s40273-013-0075-0.

Supplemental Content

Loading ...
Support Center